ArticleFrontiers in microbiology2026
Generation, characterization and epitope mapping of monoclonal antibody 4H3 specific to the HN protein of pigeon paramyxovirus type 1 (PPMV-1).
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pigeon Newcastle disease (PND), caused by pigeon paramyxovirus type 1 (PPMV-1), is an acute, highly contagious disease that induces neurological symptoms and gastrointestinal disorders in pigeons, posing substantial economic risks to the global pigeon industry. The hemagglutinin-neuraminidase (HN) protein of PPMV-1 is a key surface glycoprotein mediating viral adsorption, invasion, and egress, and serves as a critical target for vaccine development and diagnostic reagent design. In this study, we aimed to generate a specific monoclonal antibody (mAb) against the HN protein of PPMV-1 and identify its recognized epitope. We codon-optimized the conserved 198-390 amino acid (aa) region of the HN protein from PPMV-1 strain, followed by prokaryotic expression and purification to serve as the immunogen. Through cell fusion monoclonal antibody screening, we successfully established a hybridoma cell line that secretes mAb 4H3. Western blot and immunofluorescence assay (IFA) confirmed that mAb 4H3 specifically reacts with PPMV-1 strains but exhibits no cross-reactivity with the commonly used NDV vaccine strain Lasota. Epitope mapping with a panel of truncated HN protein fragments identified the minimal B-cell epitope recognized by mAb 4H3 as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.